THBS1 and melanoma: We have previously demonstrated that dynamic contrast-enhanced and diffusion weighted magnetic resonance imaging is sensitive to treatment-induced changes in the tumor microenvironment induced by bevacizumab and sunitinib treatment in melanoma xenografts, suggesting that these non-invasive imaging techniques may be used to monitor the effect of TSP-1 mimetic peptides [31, 32].